DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
Hosting Providers
CDN Services

We began analyzing https://www.tandfonline.com/doi/abs/10.4161/hv.7.0.14574, but it redirected us to https://www.tandfonline.com/doi/abs/10.4161/hv.7.0.14574. The analysis below is for the second page.

Title[redir]:
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses: Human Vaccines: Vol 7, No sup1
Description:
Prostate cancer (PCa) remains a significant public health problem. Current treatment modalities for PCa can be useful, but may be accompanied by deleterious side effects and often do not confer lon...

Matching Content Categories {📚}

Science
Social Networks
Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month

Based on our best estimate, this website will receive around 80,486,609 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

The income method remains a mystery to us.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

pca, vaccines, taylor, francis, group, page, antigen, journals, psa, psma, dna, immune, open, approach, search, codelivery, access, therapy, immunogenicity, register, human, volume, issue, journal, citations, date, electroporation, responses, received, oct, reprints, pdf, treatment, modalities, immunotherapy, antigens, targets, limited, single, prostatespecific, cellular, evaluated, vaccination, antigenspecific, ifnγ, strong, cells, research, information, solutions,

Topics {✒️}

prostate-specific membrane antigen confer long-term control psma-specific cellular immunogenicity twitter page taylor psma dna vaccines open francis group issue sup1 receive personalised research dual antigen approach strong humoral response psa-specific seroconversion journals books single antigen vaccination dna vaccines lindsey philipson-weiner deleterious side effects shown promising results species including humans date altmetric review current treatment modalities limited single antigen pca immunotherapy strategies immune therapy cellular immunogenicity journal pca treatment additional modalities important approach ifnγ date register register add cart home search published online article https attractive target immunotherapeutic approaches electroporation therapeutic targets epitope targets broader collection mouse model flow cytometry il-2 secretion data support contact newsroom email sign taylor

Schema {🗺️}

BreadcrumbList:
      context:https://schema.org
      itemListElement:
            type:ListItem
            position:1
            name:Home
            item:https://www.tandfonline.com/
            type:ListItem
            position:2
            name:All Journals
            item:https://www.tandfonline.com/action/showPublications?pubType=journal
            type:ListItem
            position:3
            name:Medicine
            item:https://www.tandfonline.com/subjects/medicine-dentistry-nursing-and-allied-health
            type:ListItem
            position:4
            name:Human Vaccines
            item:https://www.tandfonline.com/khvi19
            type:ListItem
            position:5
            name:List of Issues
            item:https://www.tandfonline.com/loi/khvi19
            type:ListItem
            position:6
            name:Volume 7, Issue sup1
            item:https://www.tandfonline.com/toc/khvi19/7/sup1
            type:ListItem
            position:7
            name:Co-delivery of PSA and PSMA DNA vaccines ....
ListItem:
      position:1
      name:Home
      item:https://www.tandfonline.com/
      position:2
      name:All Journals
      item:https://www.tandfonline.com/action/showPublications?pubType=journal
      position:3
      name:Medicine
      item:https://www.tandfonline.com/subjects/medicine-dentistry-nursing-and-allied-health
      position:4
      name:Human Vaccines
      item:https://www.tandfonline.com/khvi19
      position:5
      name:List of Issues
      item:https://www.tandfonline.com/loi/khvi19
      position:6
      name:Volume 7, Issue sup1
      item:https://www.tandfonline.com/toc/khvi19/7/sup1
      position:7
      name:Co-delivery of PSA and PSMA DNA vaccines ....
PublicationIssue:
      id:#issue
      issueNumber:sup1
      datePublished:2011-01-01
      isPartOf:
         id:#periodical
         type:
            PublicationVolume
            Periodical
         name:Human Vaccines
         issn:
            1554-8600
            1554-8619
         volumeNumber:7
         publisher:Taylor & Francis Group
["PublicationVolume","Periodical"]:
      id:#periodical
      name:Human Vaccines
      issn:
         1554-8600
         1554-8619
      volumeNumber:7
      publisher:Taylor & Francis Group
ScholarlyArticle:
      mainEntityOfPage:https://www.tandfonline.com/doi/full/10.4161/hv.7.0.14574
      url:https://www.tandfonline.com/doi/full/10.4161/hv.7.0.14574
      isPartOf:#periodical
      sameAs:https://doi.org/10.4161/hv.7.0.14574
      identifier:10.4161/hv.7.0.14574
      isAccessibleForFree:false
      articleSection:Review
      name:Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
      headline:Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses
      abstract:Prostate cancer (PCa) remains a significant public health problem. Current treatment modalities for PCa can be useful, but may be accompanied by deleterious side effects and often do not confer long-term control. Accordingly, additional modalities, such as immunotherapy, may represent an important approach for PCa treatment. The identification of tissue-specific antigens engenders PCa an attractive target for immunotherapeutic approaches. Delivery of DNA vaccines with electroporation has shown promising results for prophylactic and therapeutic targets in a variety of species including humans. Application of this technology for PCa immunotherapy strategies has been limited to single antigen and epitope targets. We sought to test the hypothesis that a broader collection of antigens would improve the breadth and effectiveness of a PCa immune therapy approach. We therefore developed highly optimized DNA vaccines encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) as a dual antigen approach to immune therapy of PCa. PSA-and PSMA-specific cellular immunogenicity was evaluated in a mouse model for co-delivery and single antigen vaccination. Mice received 2 immunizations spaced 2 weeks apart and immunogenicity was evaluated 1 week after the second vaccination. Both the PSA and PSMA vaccines induced robust antigen-specific IFNÎ³ responses by ELISpot. Further characterization of cellular immunogenicity by flow cytometry indicated strong antigen-specific TNFÎ± production by CD4+ T cells and IFNÎ³ and IL-2 secretion by both CD4+ and CD8+ T cells. There was also a strong humoral response as determined by PSA-specific seroconversion. These data support further study of this novel approach to immune therapy of PCa.
      description:Prostate cancer (PCa) remains a significant public health problem. Current treatment modalities for PCa can be useful, but may be accompanied by deleterious side effects and often do not confer long-term control. Accordingly, additional modalities, such as immunotherapy, may represent an important approach for PCa treatment. The identification of tissue-specific antigens engenders PCa an attractive target for immunotherapeutic approaches. Delivery of DNA vaccines with electroporation has shown promising results for prophylactic and therapeutic targets in a variety of species including humans. Application of this technology for PCa immunotherapy strategies has been limited to single antigen and epitope targets. We sought to test the hypothesis that a broader collection of antigens would improve the breadth and effectiveness of a PCa immune therapy approach. We therefore developed highly optimized DNA vaccines encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) as a dual antigen approach to immune therapy of PCa. PSA-and PSMA-specific cellular immunogenicity was evaluated in a mouse model for co-delivery and single antigen vaccination. Mice received 2 immunizations spaced 2 weeks apart and immunogenicity was evaluated 1 week after the second vaccination. Both the PSA and PSMA vaccines induced robust antigen-specific IFNÎ³ responses by ELISpot. Further characterization of cellular immunogenicity by flow cytometry indicated strong antigen-specific TNFÎ± production by CD4+ T cells and IFNÎ³ and IL-2 secretion by both CD4+ and CD8+ T cells. There was also a strong humoral response as determined by PSA-specific seroconversion. These data support further study of this novel approach to immune therapy of PCa.
      author:
            type:Person
            name:Niranjan Y. Sardesai
            type:Person
            name:Bernadette Ferraro
            type:Person
            name:Colleen E. Lucke
            type:Person
            name:David B. Weiner
            type:Person
            name:Kendra T. Talbott
            type:Person
            name:Neil J. Cisper
            type:Person
            name:Amir S. Khan
            type:Person
            name:Lindsey Philipson-Weiner
            type:Person
            name:David B. Weiner
      pageStart:120
      pageEnd:127
      datePublished:2011-01-01
      publisher:
         type:Organization
         name:Taylor & Francis
         logo:
            type:ImageObject
            url:https://www.tandfonline.com/pb-assets/Images/Taylor_and_Francis_Group_Logo-1742461082.png
Person:
      name:Niranjan Y. Sardesai
      name:Bernadette Ferraro
      name:Colleen E. Lucke
      name:David B. Weiner
      name:Kendra T. Talbott
      name:Neil J. Cisper
      name:Amir S. Khan
      name:Lindsey Philipson-Weiner
      name:David B. Weiner
Organization:
      name:Taylor & Francis
      logo:
         type:ImageObject
         url:https://www.tandfonline.com/pb-assets/Images/Taylor_and_Francis_Group_Logo-1742461082.png
ImageObject:
      url:https://www.tandfonline.com/pb-assets/Images/Taylor_and_Francis_Group_Logo-1742461082.png

Social Networks {👍}(4)

External Links {🔗}(105)

Analytics and Tracking {📊}

Google Analytics
Google Analytics 4
Google Tag Manager
Google Universal Analytics
Hotjar

Libraries {📚}

Dropzone.js
jQuery

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

CDN Services {📦}

Cookielaw
Optimizely
Pbgrd

2.69s.